Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26674917 | 0.77 | CCR1 (0.46) | CCR1ADORA2APIK3CAPI4KAPI4KB | |
| SCHEMBL15819692 | 0.76 | — | — | |
| SCHEMBL10399548 | 0.76 | NOS3 (0.39) | — | |
| SCHEMBL4546463 | 0.74 | CCR1 (0.43) | CCR1ADORA2A | |
| SCHEMBL11839089 | 0.73 | NOS2 (0.42) | ADORA2A | |
| SCHEMBL4903480 | 0.73 | CCR1 (0.42) | CCR1ADORA2A | |
| SCHEMBL510606 | 0.73 | CCR1 (0.42) | CCR1ADORA2APIK3CAPI4KAPI4KB | |
| SCHEMBL511107 | 0.73 | CCR1 (0.42) | CCR1ADORA2A | |
| SCHEMBL4546456 | 0.70 | ALDH1A1 (0.40) | CCR1 | |
| SCHEMBL8588461 | 0.69 | CCR1 (0.63) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | CCR1 1016/4885ADORA2A 399/4885PIK3CA 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.